{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:52:29Z","timestamp":1793987549271,"version":"4.8.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272941"],"award-info":[{"award-number":["82272941"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.pharmthera.2024.108591","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:16:05Z","timestamp":1706400965000},"page":"108591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective"],"prefix":"10.1016","volume":"254","author":[{"given":"Zhi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fada","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Bronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"494\u2013505","key":"10.1016\/j.pharmthera.2024.108591_bb0005","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after Chemoradiotherapy for localized esophageal Cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0010","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2005.04.7118","article-title":"Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102","volume":"25","author":"Bedenne","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1148\/radiol.2018172229","article-title":"Prediction of response to neoadjuvant chemotherapy and radiation therapy with baseline and restaging (18)F-FDG PET imaging biomarkers in patients with esophageal Cancer","volume":"287","author":"Beukinga","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0020","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.116.180299","article-title":"Predicting response to neoadjuvant Chemoradiotherapy in esophageal Cancer with textural features derived from pretreatment (18)F-FDG PET\/CT imaging","volume":"58","author":"Beukinga","year":"2017","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0025","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1007\/s00330-020-07439-8","article-title":"Addition of HER2 and CD44 to (18)F-FDG PET-based clinico-radiomic models enhances prediction of neoadjuvant chemoradiotherapy response in esophageal cancer","volume":"31","author":"Beukinga","year":"2021","journal-title":"European Radiology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134180","article-title":"MicroRNA-330-5p as a putative modulator of neoadjuvant Chemoradiotherapy sensitivity in Oesophageal adenocarcinoma","volume":"10","author":"Bibby","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0035","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/SLA.0000000000001911","article-title":"Molecular markers for the prediction of minor response to neoadjuvant Chemoradiation in esophageal Cancer: Results of the prospective Cologne esophageal response prediction (CERP) study","volume":"264","author":"Bollschweiler","year":"2016","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/path.5828","article-title":"Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patients","volume":"256","author":"Buck","year":"2022","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41576-020-0257-5","article-title":"Responsible, practical genomic data sharing that accelerates research","volume":"21","author":"Byrd","year":"2020","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0050","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research, N., Analysis Working Group: Asan, U., Agency, B. C. C., Brigham, Women's, H., Broad, I., et al. (2017). Integrated genomic characterization of oesophageal carcinoma. Nature, 541, 169\u2013175.","DOI":"10.1038\/nature20805"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0055","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s12859-020-03910-x","article-title":"multiGSEA: A GSEA-based pathway enrichment analysis for multi-omics data","volume":"21","author":"Canzler","year":"2020","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0060","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00535-016-1265-2","article-title":"A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma","volume":"52","author":"Chang","year":"2017","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0065","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.ijrobp.2011.02.036","article-title":"Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer","volume":"82","author":"Chen","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0070","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1245\/s10434-018-6626-z","article-title":"Identification of microRNA biomarkers of response to neoadjuvant Chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing","volume":"25","author":"Chiam","year":"2018","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173208","article-title":"Predictive value of initial FDG-PET features for treatment response and survival in esophageal cancer patients treated with chemo-radiation therapy using a random forest classifier","volume":"12","author":"Desbordes","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0080","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkw936","article-title":"The ProteomeXchange consortium in 2017: Supporting the cultural change in proteomics public data deposition","volume":"45","author":"Deutsch","year":"2017","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0085","article-title":"Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer","volume":"3","author":"Dings","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0090","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1073\/pnas.1820459116","article-title":"Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma","volume":"116","author":"Ebbing","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/path.6016","article-title":"Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer","volume":"259","author":"Eyck","year":"2023","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0100","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2217\/bmm-2017-0449","article-title":"Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach","volume":"12","author":"Fujigaki","year":"2018","journal-title":"Biomarkers in Medicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.39778","article-title":"Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with Resectable esophageal Cancer: A systematic review and Meta-analysis","volume":"5","author":"Ge","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2022.104684","article-title":"Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS","volume":"266","author":"Guo","year":"2022","journal-title":"Journal of Proteomics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0115","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007847","article-title":"High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy","volume":"11","author":"Han","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0125","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/ng.3683","article-title":"Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma","volume":"48","author":"Hao","year":"2016","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0130","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1158\/1078-0432.CCR-05-0656","article-title":"Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling","volume":"11","author":"Hayashida","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0135","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.21037\/jgo-20-504","article-title":"Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma","volume":"11","author":"He","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0140","series-title":"Identification of novel molecular subgroups in esophageal adenocarcinoma to predict response to neo-adjuvant therapies","author":"Hoefnagel","year":"2022"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0145","first-page":"14","article-title":"Circulating tumor DNA-based disease monitoring of patients with locally advanced esophageal cancer","author":"Hofste","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0150","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.21037\/jtd.2018.03.123","article-title":"Radiomic analysis in T2W and SPAIR T2W MRI: Predict treatment response to chemoradiotherapy in esophageal squamous cell carcinoma","volume":"10","author":"Hou","year":"2018","journal-title":"Journal of Thoracic Disease"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0155","doi-asserted-by":"crossref","first-page":"104444","DOI":"10.18632\/oncotarget.22304","article-title":"Radiomic analysis in contrast-enhanced CT: Predict treatment response to chemoradiotherapy in esophageal carcinoma","volume":"8","author":"Hou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0160","doi-asserted-by":"crossref","first-page":"10291","DOI":"10.1038\/srep10291","article-title":"Circulating mRNA profiling in esophageal squamous cell carcinoma identifies FAM84B as a biomarker in predicting pathological response to neoadjuvant Chemoradiation","volume":"5","author":"Hsu","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0165","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15927","article-title":"Assessment of Intratumoral and Peritumoral computed tomography Radiomics for predicting pathological complete response to neoadjuvant Chemoradiation in patients with esophageal squamous cell carcinoma","volume":"3","author":"Hu","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0170","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.radonc.2020.09.014","article-title":"Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma","volume":"154","author":"Hu","year":"2021","journal-title":"Radiotherapy and Oncology"},{"issue":"1682\u20131697","key":"10.1016\/j.pharmthera.2024.108591_bb0175","article-title":"Identification of subtypes of Barrett\u2019s esophagus and esophageal adenocarcinoma based on DNA methylation profiles and integration of transcriptome and genome data","volume":"158","author":"Jammula","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0180","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.21873\/invivo.12448","article-title":"A Meta-analysis for using Radiomics to predict complete pathological response in esophageal Cancer patients receiving neoadjuvant Chemoradiation","volume":"35","author":"Kao","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100685","article-title":"Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy","volume":"45","author":"Kim","year":"2021","journal-title":"Current Problems in Cancer"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015074","article-title":"Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome","volume":"5","author":"Kim","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/1878-0261.12907","article-title":"Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies","volume":"15","author":"de Klerk","year":"2021","journal-title":"Molecular Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0200","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.athoracsur.2012.04.145","article-title":"MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy","volume":"94","author":"Ko","year":"2012","journal-title":"The Annals of Thoracic Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0205","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)31462-9","article-title":"Oesophageal cancer","volume":"390","author":"Lagergren","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0210","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: The bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0215","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/ng.3312","article-title":"The European genome-phenome archive of human data consented for biomedical research","volume":"47","author":"Lappalainen","year":"2015","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12929-018-0468-7","article-title":"Tumor xenograft animal models for esophageal squamous cell carcinoma","volume":"25","author":"Lee","year":"2018","journal-title":"Journal of Biomedical Science"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0225","article-title":"Radiomics signature facilitates organ-saving strategy in patients with esophageal squamous cell Cancer receiving neoadjuvant Chemoradiotherapy","volume":"10","author":"Li","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276990","article-title":"AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma","volume":"17","author":"Lin","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0235","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00262-022-03288-0","article-title":"PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma","volume":"72","author":"Liu","year":"2023","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0240","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/1759-7714.14873","article-title":"COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy","volume":"14","author":"Liu","year":"2023","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0245","article-title":"GraphCDR: A graph neural network method with contrastive learning for cancer drug response prediction","volume":"23","author":"Liu","year":"2022","journal-title":"Briefings in Bioinformatics"},{"issue":"181\u2013195","key":"10.1016\/j.pharmthera.2024.108591_bb0250","article-title":"Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0255","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fendo.2019.00835","article-title":"Multiomics-based signaling pathway network alterations in human non-functional pituitary adenomas","volume":"10","author":"Long","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0260","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2005.03.3688","article-title":"Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation","volume":"24","author":"Luthra","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0265","doi-asserted-by":"crossref","DOI":"10.2119\/molmed.2016.00020","article-title":"Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma","volume":"22","author":"Lynam-Lennon","year":"2016","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0270","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00109-012-0924-x","article-title":"MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma","volume":"90","author":"Lynam-Lennon","year":"2012","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0275","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/SLA.0b013e3181bce7e1","article-title":"Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer","volume":"250","author":"Maher","year":"2009","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0280","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/SLA.0b013e31823699f2","article-title":"Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation","volume":"254","author":"Maher","year":"2011","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0285","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40364-022-00429-6","article-title":"Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma","volume":"10","author":"Matani","year":"2022","journal-title":"Biomarker Research"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature18003","article-title":"Proteogenomics connects somatic mutations to signalling in breast cancer","volume":"534","author":"Mertins","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0295","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/pgs.10.76","article-title":"CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer","volume":"11","author":"Metzger","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0300","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11605-011-1700-x","article-title":"Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis","volume":"16","author":"Metzger","year":"2012","journal-title":"Journal of Gastrointestinal Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0530","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1038\/s41467-023-38891-x","article-title":"Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy","volume":"14","author":"M","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0305","article-title":"Predicting the local response of esophageal squamous cell carcinoma to neoadjuvant Chemoradiotherapy by Radiomics with a machine learning method using (18)F-FDG PET images","volume":"11","author":"Murakami","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0310","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/bjs.10627","article-title":"Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma","volume":"104","author":"Noble","year":"2017","journal-title":"The British Journal of Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0315","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S1470-2045(18)30201-8","article-title":"Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): A prospective multicentre, diagnostic cohort study","volume":"19","author":"Noordman","year":"2018","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0320","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/ijc.28253","article-title":"MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response","volume":"133","author":"Odenthal","year":"2013","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0325","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-019-0609-x","article-title":"Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma","volume":"7","author":"Park","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0330","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/his.13811","article-title":"Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?","volume":"74","author":"Puetz","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0335","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41580-019-0108-4","article-title":"Identification of bioactive metabolites using activity metabolomics","volume":"20","author":"Rinschen","year":"2019","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0340","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/1754-9485.13128","article-title":"Pretreatment CT and (18) F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer","volume":"65","author":"Rishi","year":"2021","journal-title":"Journal of Medical Imaging and Radiation Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0345","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2967\/jnumed.115.163766","article-title":"The incremental value of subjective and quantitative assessment of 18F-FDG PET for the prediction of pathologic complete response to preoperative Chemoradiotherapy in esophageal Cancer","volume":"57","author":"van Rossum","year":"2016","journal-title":"Journal of Nuclear Medicine"},{"issue":"3367\u20133373","key":"10.1016\/j.pharmthera.2024.108591_bb0350","article-title":"A deep learning framework for predicting response to therapy in Cancer","volume":"29","author":"Sakellaropoulos","year":"2019","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0355","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0360","doi-asserted-by":"crossref","first-page":"6647597","DOI":"10.1155\/2021\/6647597","article-title":"Bias in RNA-seq library preparation: Current challenges and solutions","volume":"2021","author":"Shi","year":"2021","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0365","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12967-018-1492-9","article-title":"MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus","volume":"16","author":"Slotta-Huspenina","year":"2018","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0370","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0375","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00432-014-1841-x","article-title":"ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy","volume":"141","author":"Takahashi","year":"2015","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0380","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/s41467-020-16937-8","article-title":"Harmonization of quality metrics and power calculation in multi-omic studies","volume":"11","author":"Tarazona","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0385","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12876-018-0823-x","article-title":"Metabolomic and BH3 profiling of esophageal cancers: Novel assessment methods for precision therapy","volume":"18","author":"Taylor Ripley","year":"2018","journal-title":"BMC Gastroenterology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0390","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12967-014-0233-y","article-title":"Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma","volume":"12","author":"Tong","year":"2014","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0395","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41576-023-00580-2","article-title":"Methods and applications for single-cell and spatial multi-omics","volume":"24","author":"Vandereyken","year":"2023","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0400","doi-asserted-by":"crossref","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","article-title":"LinkedOmics: Analyzing multi-omics data within and across 32 cancer types","volume":"46","author":"Vasaikar","year":"2018","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0405","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12859-016-1273-5","article-title":"Handling missing rows in multi-omics data integration: Multiple imputation in multiple factor analysis framework","volume":"17","author":"Voillet","year":"2016","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0410","article-title":"DeepDRK: A deep learning framework for drug repurposing through kernel-based multi-omics integration","volume":"22","author":"Wang","year":"2021","journal-title":"Briefings in Bioinformatics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0415","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/pgs.09.137","article-title":"TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer","volume":"11","author":"Warnecke-Eberz","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0420","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s11605-009-0881-z","article-title":"ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer","volume":"13","author":"Warnecke-Eberz","year":"2009","journal-title":"Journal of Gastrointestinal Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104371","article-title":"Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma","volume":"86","author":"Wen","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0430","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/SLA.0000000000001489","article-title":"MiRNA expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neoadjuvant Chemoradiotherapy","volume":"263","author":"Wen","year":"2016","journal-title":"Annals of Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0435","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/annonc\/mdu201","article-title":"Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy","volume":"25","author":"Wen","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0440","first-page":"1237","article-title":"Population and singlecell transcriptome analyses reveal diverse transcriptional changes associated with radioresistance in esophageal squamous cell carcinoma","volume":"55","author":"Wu","year":"2019","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0445","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1200\/JCO.2005.03.6640","article-title":"Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer","volume":"24","author":"Wu","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0450","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant Chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0455","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ijrobp.2023.06.005","article-title":"Genomic and transcriptomic remodelling by neoadjuvant chemoradiotherapy (nCRT) and indicative role of acquired INDEL percentage for nCRT efficacy in esophageal squamous cell carcinoma","volume":"Physics,117,","author":"Yang","year":"2023","journal-title":"International Journal of Radiation Oncology, Biology"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0460","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/JS9.0000000000000441","article-title":"The gap before real clinical application of imaging-based machine-learning and radiomic models for chemoradiation outcome prediction in esophageal cancer: A systematic review and meta-analysis","volume":"109","author":"Yang","year":"2023","journal-title":"International Journal of Surgery"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0465","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jrr\/rrz027","article-title":"CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy","volume":"60","author":"Yang","year":"2019","journal-title":"Journal of Radiation Research"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106678","article-title":"Noncoding RNAs in esophageal cancer: A glimpse into implications for therapy resistance","volume":"188","author":"Yang","year":"2023","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137036","article-title":"Predicting response to neoadjuvant chemotherapy with PET imaging using convolutional neural networks","volume":"10","author":"Ypsilantis","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0480","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41551-018-0305-z","article-title":"Artificial intelligence in healthcare","volume":"2","author":"Yu","year":"2018","journal-title":"Nature Biomedical Engineering"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215959","article-title":"Th1-involved immune infiltrates improve neoadjuvant chemoradiotherapy response of esophageal squamous cell carcinoma","volume":"553","author":"Yuan","year":"2023","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0490","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature13438","article-title":"Proteogenomic characterization of human colon and rectal cancer","volume":"513","author":"Zhang","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0495","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.156","article-title":"A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy","volume":"10","author":"Zhang","year":"2020","journal-title":"Clinical and Translational Medicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104515","article-title":"Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: A single-center, open-label, single-arm phase 2 trial","volume":"90","author":"Zhang","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0505","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2013.09.037","article-title":"Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics","volume":"88","author":"Zhang","year":"2014","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0510","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.21037\/jtd-20-230","article-title":"The mutation profiles of cell-free DNA in patients with oesophageal squamous cell carcinoma who were responsive and non-responsive to neoadjuvant chemotherapy","volume":"12","author":"Zhang","year":"2020","journal-title":"Journal of Thoracic Disease"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0515","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3892\/etm.2022.11728","article-title":"Altered genome-wide hydroxymethylation analysis for neoadjuvant chemoradiotherapy followed by surgery in esophageal cancer","volume":"25","author":"Zhang","year":"2023","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0520","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1186\/s12885-020-07336-9","article-title":"Alteration of plasma metabolites associated with chemoradiosensitivity in esophageal squamous cell carcinoma via untargeted metabolomics approach","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2024.108591_bb0525","article-title":"Proteomic analysis to identify markers for response to neoadjuvant treatment in esophageal and gastroesophageal cancer","volume":"5","author":"Zlotnik","year":"2021","journal-title":"Cancer Rep (Hoboken)"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:34:20Z","timestamp":1759012460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":106,"alternative-id":["S0163725824000111"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108591","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108591"}}